June 12, 2013
Eisai said on June 10 that its experimental anticancer agent lenvatinib as an add-on therapy to dacarbazine demonstrated a statistically significant increase in progression free survival (PFS) in patients with Stage IV chemotherapy-naive melanoma, compared to dacarbazine alone. Lenvatinib is...read more